gsk news - Search News

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

The Wall Street Journal on MSN · 5h

GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.

U.S. News & World Report · 6h

GSK Reaches up to $2.2 Billion Settlement in Zantac US State Court Cases

(Reuters) - GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion. Copyright 2024 Thomson Reuters.

48mon MSN

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday

Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...

1d

GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

2h

GSK Options Trading: A Deep Dive into Market Sentiment

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

12h

GlaxoSmithKline (GSK) Receives a Hold from Goldman Sachs

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

11h

GSK reports positive findings from Phase III RSV vaccine trial

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

1don MSN

GSK RSV shot 43% effective against severe disease in third year

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results